Table 2.
Cell Cycle Inhibitors [2]
| Cell Cycle Inhibitor | Mechanism of Action | Effects | Clinical Trials* |
|---|---|---|---|
| flavopiridol | Inhibits CDK 2, 4, 6, 9 | G1/S arrest | Phase I/II (hematologic and several solid tumors) |
| Roscovitine | Inhibits cyclinE/CDK2, cyclinB/CDK1, cyclinH/CDK7, cyclinT1/CDK9; p53 activation, NF-κB, decreases Mcl-1 | S/G2/M arrest | Phase I/II (solid tumors) |
| E7070 | Inhibits CDK2, cyclin E | G1/S progression | Phase I/II (several solid tumors, melanoma) |
| SNS-032 | Inhibits CDK 2, 7, 9, VEGF | Inhibits progression and transcription, angiogenesis | Phase I (advanced B-cell lymphomas, several solid tumors) |
| bryostatin-1 | Affects protein kinase C, CDK2; induces p21 | Cell cycle modulation | Phase I/II (combination therapy for hematologic and several solid tumors) |
| AZD5438 | Inhibits CDK1, 2, 9 | Affects all phases of cell cycle | Trials terminated dues to safety concerns |